share_log

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

Important Biotech Catalysts For September 14, 2022 - End Of The Day Summary

2022年9月14日的重要生物技术催化剂-当天结束摘要
Benzinga Real-time News ·  2022/09/14 17:32
The U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of TRACON's (NASDAQ:TCON) lead asset envafolimab (KN035) for patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS) and myxofibrosarcoma (MFS) who have progressed on one or two prior lines of chemotherapy. TRACON shares traded as high as 5.26 percent, in a range of $1.9 to $2 on day volume of 111.77 thousand shares, closed regular trading session at $1.9.
美国食品和药物管理局(FDA)已批准快车道指定用于开发TRACON纳斯达克(TCon)的主导资产envafolimab(KN035)适用于局部晚期、无法切除或转移性未分化的多形性肉瘤(UPS)和粘液纤维肉瘤(MFS)患者,这些患者在既往的一到两个化疗方案中取得了进展。TRACON的股票交易价格高达5.26%,当日成交量为111.77万股,在1.9美元到2美元的范围内,常规交易时段收盘报1.9美元。
Centessa Pharmaceuticals (NASDAQ:CNTA) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to SerpinPC for the treatment of hemophilia B...
Centessa制药公司纳斯达克(Sequoia Ca...
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发